首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Pharmacogenomics & Personalized Medicine

Pharmacogenomics & Personalized Medicine杂志,由Dove Medical Press出版,1 issue/year,出版语言English,ISSN:1178-7066,E-ISSN:1178-7066。

投稿咨询
Pharmacogenomics & Personalized Medicine
Pharmacogenomics & Personalized Medicine
Pharmacogenomics & Personalized Medicine
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
4区
影响因子
2.4
CiteScore
4.8
期刊收录
SCI、SCIE

Pharmacogenomics & Personalized Medicine(中文译名:《药物基因组学和个性化医学》),ISSN:1178-7066,EISSN:1178-7066,是Dove Medical Press出版的国际性学术期刊,以1 issue/year形式稳定发行,2026年总发文量约23篇。该刊采用OA开放访问,学科归属为Biochemistry, Genetics and Molecular Biology - Molecular Medicine。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.4,2025年期刊CiteScore为4.8,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Pharmacogenomics & Personalized Medicine长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期16 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、Jordan、Russia、Saudi Arabia、Spain、Italy等为核心发文国家与地区;JORDAN UNIVERSITY OF SCIENCE & TECHNOLOGYKING KHALID UNIVERSITY、SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY、HARVARD UNIVERSITY、NANJING MEDICAL UNIVERSITY、CHULALONGKORN UNIVERSITY、JIANGSU UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
PHARMACOLOGY & PHARMACY 药学
4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
PHARMACOLOGY & PHARMACY 药学
4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q3 215 / 356

39.7

学科:PHARMACOLOGY & PHARMACY SCIE Q3 215 / 356

39.75

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q3 240 / 354

32.3

学科:PHARMACOLOGY & PHARMACY SCIE Q3 215 / 354

39.41


中国学者近期发文

1
Construction and Validation of Multi-Omics Predictive Models for Colorectal Cancer Using Machine-Learning Approache

Author:Lu, Zhenhuan; Li, Xiaowen; Liang, Zhiping; Zhang, Xiaocong; Tan, Yiyan; Kuang, Yinglan; Li, Kang; Zhu, Xiaofeng

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/PGPM.S566928

2
Massive Hepatocellular Carcinoma with Insufficient Future Liver Remnant Achieved Complete Response After Two-Stage Hepatectomy Combined with Hepatic Arterial Infusion Chemotherapy and Lenvatinib-sintilimab: A Case Repor

Author:Xu, Ruoxiang; Zhang, Mingrui; Zeng, Zhiming; Wei, Yongguang; Liao, Xiwen; Yang, Chengkun; Peng, Tao; Su, Hao

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/PGPM.S578577

3
Post-Translational Modifications of Histones and Non-Histones in Liver Disease and Traditional Chinese Medicine Treatment: A Narrative Revie

Author:Xie, Zhuohua; Deng, Yanting; Zhang, Xinru; Chen, Jieyi; Deng, Jiasheng; Fang, Yibin; Ye, Xiaoxue; Zhou, Zhipin

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/PGPM.S555701

4
Clinical Outcomes of Osimertinib Combined with Platinum-Based Chemotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Stud

Author:Han, Ruixue; Yu, Xin

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/PGPM.S566952

5
Bioinformatic Identification and Preliminary Validation of TP53, TGFB1, and NFE2L2 as Potential Ferroptosis-Related Regulators in Pancreatic Adenocarcinom

Author:Li, Shouying; Zhang, Chunfang; Lv, Shengxiang; Zhang, Zhimei; Xu, Dazhou; Xu, Tonglei

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/PGPM.S562602

6
Associations Between FTO Polymorphisms and Neuroblastoma Risk in Chinese Childre

Author:Liu, Peiqi; Li, Yue; Li, Yong; Li, Li; Cheng, Jiwen; Li, Suhong; Zhang, Jiao; Zhou, Haixia; Huo, Yunlong; Yang, Zhonghua; He, Jing; Zhang, Ran

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2025; Vol. 18, Issue , pp. 143-151. DOI: 10.2147/PGPM.S488314

7
Molecular Genetic Analysis of a DMD Frameshift Mutation in a Boy with Duchenne Muscular Dystrophy by MLPA and Sanger Sequencin

Author:Chen, Qianwen; Zhang, Wenjuan; Zha, Lingfeng

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2025; Vol. 18, Issue , pp. 153-162. DOI: 10.2147/PGPM.S514145

8
Novel SLC16A2 Frameshift Mutation as a Cause of Allan-Herndon-Dudley Syndrome and its Implications for Carrier Screenin

Author:Lin, Peng; Liu, Huituan; Lou, Jiwu; Lyu, Guizhen; Li, Yanwei; He, Peiqing; Fu, Youqing; Zhang, Ronghua; Zhang, Yuqiong; Yan, Tizhen

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2025; Vol. 18, Issue , pp. 85-94. DOI: 10.2147/PGPM.S492647

9
Clinicopathological and Molecular Features of Primary Inflammatory Myofibroblastic Tumor in Nasal Cavity and Paranasal Sinuse

Author:Zhao, Yihua; Ma, Donglin; Wan, Hongfei; Piao, Yingshi

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2025; Vol. 18, Issue , pp. 95-104. DOI: 10.2147/PGPM.S508156

10
Prevalence of CYP2C19 Variants in Patients with Cardiovascular Disease from the Yunnan-Guizhou Plateau in Southwestern Chin

Author:Li, Xiu-Ping; Wang, Jun-Ling; Lei, San-Xi; Chen, Bo-Yu; Ma, Xiang; He, Fei; Yue, Chao-Fu; Liu, Hong-Xia; Hu, Jian-Peng; Xiong, Qian; Ji, Ting; Zhang, Zheng-Fu; Sun, Yong; Li, Hong-Wei

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2025; Vol. 18, Issue , pp. 105-113. DOI: 10.2147/PGPM.S509794


在线咨询

Pharmacogenomics & Personalized Medicine

国际简称:PHARMACOGEN PERS MED参考译名:药物基因组学和个性化医学

年发文量:23 CiteScore:4.8 是否预警:否 Gold OA文章占比:98.73% 研究类文章占比:78.26%

杂志社联系方式:PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752

Pharmacogenomics & Personalized Medicine